Cyclo Therapeutics Inc - Ordinary Shares - Class A

NASDAQ:CYTH 1:04:29 PM EDT

10.83

+0.27 (+2.56%)

Market Cap (Intraday)	68.87M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$0.29 Million
Adjusted EPS	-$0.41

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

Cyclo Therapeutics Inc - Ordinary Shares - Class A Stock, NASDAQ:CYTH

6714 NW 16th Street, Suite B, Gainesville, Florida 32653

United States of America

Phone: +1.386.418.8060

Number of Employees: 8

http://www.ctd-holdings.com

Description

Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product candidates include Trappsol Cyclo, which treats Neimann-Pick Type C disease. The firm focuses on the development and commercialization of innovative cyclodextrin-based products for the treatment of people with serious and life threatening rare diseases and medical conditions. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.